Search
for
Sort by
Research 121–150 of 1000+
- Alopecia Areata – Effects of Treatment with Upadacitinib – Two Case Reports
- Under Development JAK Inhibitors for Dermatologic Diseases
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Ruxolitinib: A novel molecule in the management of dermatological disorders
- Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications beyond Atopic Dermatitis
- Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
- Successful treatment of severe diffuse alopecia areata with abrocitinib
- S3886 Concurrent Management of Crohn's Ileitis and Alopecia Universalis With Upadacitinib
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- Autophagy Stimulation Improves Erythroid Proliferative Capacity in Models of SF3B1 Mutant MDS
- Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
- Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
- Successful treatment of alopecia universalis with abrocitinib: a case report
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib
- Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review
- Tofacitinib Treatment in Patients With Active COVID-19 Infection
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
- Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
- JAK Family Expression and Therapeutic Implications in Primary Cicatricial Alopecias
- Abrocitinib in the Treatment of Severe Alopecia Areata in a Pediatric Patient: A Case Report
- Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil.
- Hair follicle stem cells and the collapse of self-tolerance in alopecia: the interplay of barrier function, the microbiome, and immunity
- 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS)